TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02494193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial caries removal
Description: The caries infected dentin will be removed mantaining the affected caries tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial caries removal
Description: The caries infected dentin will be removed mantaining the affected caries tissue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provisional restoration - control
Description: After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provisional restoration - experimental
Description: After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total caries removal
Description: After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total caries removal
Description: After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Definitive restoration
Description: Definite restoration will be performed using composite.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Definitive restoration
Description: Definite restoration will be performed using composite.
Study: NCT03935126

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostics
Description: Diagnostics
Study: NCT02520726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: \< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matched encapsulated placebo from 1-4 capsules daily
Study: NCT00768612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCA-136 50mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCA-136 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCA-136 300mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 4mg/day
Study: NCT02655848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic rotator cuff repair using suture anchors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic rotator cuff repair using suture anchors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LHB Tenodesis
Description: Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LHB Tenotomy
Description: Arthroscopic tenotomy of long head biceps
Study: NCT03151044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Epirubicin Combined with CVP ± Rituximab
Description: Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose Epirubicin Combined with CVP ± Rituximab
Description: Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
Study: NCT02179008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Low Dose ophthalmic solution
Description: Low Dose DE-117 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Low/Middle Dose ophthalmic solution
Description: Low/Middle Dose DE-117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Middle Dose ophthalmic solution
Description: Middle Dose DE-117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Middle/High Dose ophthalmic solution
Description: Middle/High Dose DE-117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 High Dose ophthalmic solution
Description: High Dose DE-117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost ophthalmic solution 0.005%
Description: 0.005% latanoprost
Study: NCT03298802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50mg Tablet
Description: Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
Study: NCT03838185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: J147
Description: Single oral dose of J147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of corn oil
Study: NCT01815723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: 500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: 720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP187 placebo
Description: FP187 matching placebo tablets in the same regimen as for FP187 arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP187 placebo
Description: FP187 matching placebo tablets in the same regimen as for FP187 arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fumaderm® placebo
Description: Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fumaderm® placebo
Description: Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
Study: NCT04281407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: 2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
Study: NCT00596414

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transjugular liver biopsy
Description: liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transjugular liver biopsy
Description: liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transjugular liver biopsy
Description: liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam + pethidine
Study: NCT00918385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilutamide
Description: Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
Study: NCT00322881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03389022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0,15 mg/kg pre-incisional single bolus dose of ketamine in the operating room.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous injection given pre-incisional in the operating room.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0,3 mg/kg pre-incisional single bolus dose of ketamine in the operating room.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0,15 mg/kg pre-incisional single bolus dose of ketamine, followed by continuous infusion of 1 mg/kg in the operating room.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
Study: NCT04499755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleo CMP Forte
Description: Nucleo CMP Forte twice daily for 6 weeks
Study: NCT03261336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol, Ketoconazole, Hydrocortisone
Description: Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
Study: NCT00254917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine
Description: 0.5 mL, IM
Study: NCT01528059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stomach-small intestine reconstruction
Description: Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stomach-small intestine reconstruction
Description: Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
Study: NCT02475239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural restriction
Description: The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal daily activity
Description: The patients did not follow any postural restrictions and were asked to live as normally as possible.
Study: NCT00002643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study: NCT03685851

Intervention type: PROCEDURE
Intervention: DSAEK type corneal transplant
Description: All surgeries were performed by the same surgeon and according to the same protocol
Study: NCT00002643

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT02470559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2Bi-Armed Activated T Cells
Description: Given IV and IP
Study: NCT02779439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus specific CTLs
Description: Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
Study: NCT02848469

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid
Study: NCT00435916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: 1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
Study: NCT02774460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestril®
Description: Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atacand®
Description: Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc®
Description: Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide®
Description: Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment X
Description: Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Y
Description: Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
Study: NCT01616628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable rewards
Description: Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
Study: NCT04235517

Intervention type: OTHER
Intervention: Temporary hemi-epiphysiodesis or epiphysiodesis
Description: Tension band plate (eight-plate, pedi plate), staple or locking plate

Intervention type: OTHER
Intervention: Temporary hemi-epiphysiodesis or epiphysiodesis
Description: Tension band plate (eight-plate, pedi plate), staple or locking plate
Study: NCT00561652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education & Exercise
Description: Education \& Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education & Exercise
Description: Education \& Exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment (plus Education & Exercise)
Description: Chiropractic treatment (plus Education \& Exercise)
Study: NCT02470559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT02531347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure measurements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional blood pressure monitoring
Study: NCT03341416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation on stimulation - active
Description: bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation off stimulation - sham
Description: bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
Study: NCT02978417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone for extended-release injectable suspension
Description: Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
Study: NCT03972566

Intervention type: DRUG
Intervention: INOMAX
Description: INOMAX + PBM
Study: NCT01975870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application on smartphone
Description: innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
Study: NCT03375567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Lesion Biopsies
Description: After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
Study: NCT02329652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Networked Neuroprosthetic System for Grasp and Trunk
Description: Receive implanted networked neuroprosthesis
Study: NCT03295721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo by instillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl without epinephrine, 50 mg by injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer-lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Luer-lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product
Study: NCT03922438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
Description: Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
Study: NCT03602768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory & Aging Program
Description: Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cambridge Brain Sciences
Description: Commercial brain training software available for subscription to the general public and for research studies.
Study: NCT03060005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: This medication is used to relieve dry, irritated eyes
Study: NCT03375567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lesion Biopsies
Description: After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
Study: NCT00928018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Taken orally for at least 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given intravenously on the first, third and sixth day after transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given intravenously on the first, third and sixth day after transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Taken orally or given intravenously for at least 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Taken orally or given intravenously for at least 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Taken orally or given intravenously for at least 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: Taken orally for about 2 months
Study: NCT03732560

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03060005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposic
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.